|
Gene: FBXO31 |
Gene summary for FBXO31 |
Gene summary. |
Gene information | Species | Human | Gene symbol | FBXO31 | Gene ID | 79791 |
Gene name | F-box protein 31 | |
Gene Alias | FBX14 | |
Cytomap | 16q24.2 | |
Gene Type | protein-coding | GO ID | GO:0000075 | UniProtAcc | A0A0C4DGU8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79791 | FBXO31 | LZE4T | Human | Esophagus | ESCC | 2.48e-03 | 7.87e-02 | 0.0811 |
79791 | FBXO31 | LZE7T | Human | Esophagus | ESCC | 4.09e-08 | 3.26e-01 | 0.0667 |
79791 | FBXO31 | LZE24T | Human | Esophagus | ESCC | 1.06e-08 | 2.31e-01 | 0.0596 |
79791 | FBXO31 | LZE21T | Human | Esophagus | ESCC | 3.93e-05 | 2.26e-01 | 0.0655 |
79791 | FBXO31 | P1T-E | Human | Esophagus | ESCC | 1.92e-05 | 2.22e-01 | 0.0875 |
79791 | FBXO31 | P2T-E | Human | Esophagus | ESCC | 7.48e-14 | 1.97e-01 | 0.1177 |
79791 | FBXO31 | P4T-E | Human | Esophagus | ESCC | 4.52e-10 | 1.49e-01 | 0.1323 |
79791 | FBXO31 | P5T-E | Human | Esophagus | ESCC | 2.16e-12 | 1.33e-01 | 0.1327 |
79791 | FBXO31 | P8T-E | Human | Esophagus | ESCC | 5.91e-07 | 1.10e-01 | 0.0889 |
79791 | FBXO31 | P9T-E | Human | Esophagus | ESCC | 1.41e-07 | 1.61e-01 | 0.1131 |
79791 | FBXO31 | P10T-E | Human | Esophagus | ESCC | 3.28e-03 | 8.06e-02 | 0.116 |
79791 | FBXO31 | P11T-E | Human | Esophagus | ESCC | 1.60e-09 | 2.49e-01 | 0.1426 |
79791 | FBXO31 | P12T-E | Human | Esophagus | ESCC | 7.67e-21 | 2.90e-01 | 0.1122 |
79791 | FBXO31 | P15T-E | Human | Esophagus | ESCC | 1.79e-18 | 3.98e-01 | 0.1149 |
79791 | FBXO31 | P16T-E | Human | Esophagus | ESCC | 1.74e-14 | 1.55e-01 | 0.1153 |
79791 | FBXO31 | P19T-E | Human | Esophagus | ESCC | 3.60e-02 | 3.32e-01 | 0.1662 |
79791 | FBXO31 | P20T-E | Human | Esophagus | ESCC | 3.35e-12 | 2.17e-01 | 0.1124 |
79791 | FBXO31 | P21T-E | Human | Esophagus | ESCC | 2.59e-11 | 1.69e-01 | 0.1617 |
79791 | FBXO31 | P22T-E | Human | Esophagus | ESCC | 3.47e-15 | 2.88e-01 | 0.1236 |
79791 | FBXO31 | P23T-E | Human | Esophagus | ESCC | 6.74e-13 | 3.02e-01 | 0.108 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
GO:0043161111 | Esophagus | ESCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 312/8552 | 412/18723 | 3.53e-36 | 4.48e-33 | 312 |
GO:004477216 | Esophagus | ESCC | mitotic cell cycle phase transition | 281/8552 | 424/18723 | 4.63e-18 | 4.45e-16 | 281 |
GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
GO:190198713 | Esophagus | ESCC | regulation of cell cycle phase transition | 242/8552 | 390/18723 | 3.86e-11 | 1.26e-09 | 242 |
GO:190199013 | Esophagus | ESCC | regulation of mitotic cell cycle phase transition | 191/8552 | 299/18723 | 1.35e-10 | 3.94e-09 | 191 |
GO:00457865 | Esophagus | ESCC | negative regulation of cell cycle | 236/8552 | 385/18723 | 3.62e-10 | 9.93e-09 | 236 |
GO:00000754 | Esophagus | ESCC | cell cycle checkpoint | 117/8552 | 169/18723 | 4.47e-10 | 1.17e-08 | 117 |
GO:004277014 | Esophagus | ESCC | signal transduction in response to DNA damage | 117/8552 | 172/18723 | 2.38e-09 | 5.32e-08 | 117 |
GO:00070934 | Esophagus | ESCC | mitotic cell cycle checkpoint | 90/8552 | 129/18723 | 2.49e-08 | 4.69e-07 | 90 |
GO:00109484 | Esophagus | ESCC | negative regulation of cell cycle process | 177/8552 | 294/18723 | 3.26e-07 | 4.59e-06 | 177 |
GO:000008214 | Esophagus | ESCC | G1/S transition of mitotic cell cycle | 134/8552 | 214/18723 | 4.04e-07 | 5.55e-06 | 134 |
GO:004484314 | Esophagus | ESCC | cell cycle G1/S phase transition | 148/8552 | 241/18723 | 5.68e-07 | 7.48e-06 | 148 |
GO:00315705 | Esophagus | ESCC | DNA integrity checkpoint | 83/8552 | 123/18723 | 8.17e-07 | 1.06e-05 | 83 |
GO:00000775 | Esophagus | ESCC | DNA damage checkpoint | 78/8552 | 115/18723 | 1.27e-06 | 1.56e-05 | 78 |
GO:19019883 | Esophagus | ESCC | negative regulation of cell cycle phase transition | 151/8552 | 249/18723 | 1.28e-06 | 1.57e-05 | 151 |
GO:004593013 | Esophagus | ESCC | negative regulation of mitotic cell cycle | 143/8552 | 235/18723 | 1.84e-06 | 2.15e-05 | 143 |
GO:190199113 | Esophagus | ESCC | negative regulation of mitotic cell cycle phase transition | 112/8552 | 179/18723 | 3.69e-06 | 4.03e-05 | 112 |
GO:002260420 | Esophagus | ESCC | regulation of cell morphogenesis | 180/8552 | 309/18723 | 5.19e-06 | 5.45e-05 | 180 |
GO:003134616 | Esophagus | ESCC | positive regulation of cell projection organization | 201/8552 | 353/18723 | 1.19e-05 | 1.11e-04 | 201 |
Page: 1 2 3 4 5 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FBXO31 | SNV | Missense_Mutation | novel | c.551N>G | p.Asp184Gly | p.D184G | Q5XUX0 | protein_coding | tolerated(1) | possibly_damaging(0.612) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FBXO31 | SNV | Missense_Mutation | novel | c.422N>A | p.Arg141Gln | p.R141Q | Q5XUX0 | protein_coding | deleterious(0.04) | benign(0.014) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FBXO31 | SNV | Missense_Mutation | c.1429N>A | p.Gly477Ser | p.G477S | Q5XUX0 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-BG-A0MQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
FBXO31 | SNV | Missense_Mutation | rs187880966 | c.1082N>A | p.Arg361His | p.R361H | Q5XUX0 | protein_coding | tolerated(0.12) | benign(0.005) | TCGA-BS-A0TJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FBXO31 | SNV | Missense_Mutation | rs756439061 | c.625G>A | p.Gly209Ser | p.G209S | Q5XUX0 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FBXO31 | SNV | Missense_Mutation | novel | c.1054N>T | p.Ile352Phe | p.I352F | Q5XUX0 | protein_coding | deleterious(0) | benign(0.308) | TCGA-D1-A2G5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
FBXO31 | SNV | Missense_Mutation | rs749513403 | c.1193G>A | p.Arg398Gln | p.R398Q | Q5XUX0 | protein_coding | tolerated(0.62) | benign(0) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FBXO31 | SNV | Missense_Mutation | novel | c.767N>A | p.Arg256His | p.R256H | Q5XUX0 | protein_coding | deleterious(0.03) | probably_damaging(0.996) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FBXO31 | SNV | Missense_Mutation | c.365N>A | p.Arg122Gln | p.R122Q | Q5XUX0 | protein_coding | tolerated(1) | probably_damaging(0.992) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
FBXO31 | SNV | Missense_Mutation | c.1609N>T | p.Leu537Phe | p.L537F | Q5XUX0 | protein_coding | tolerated(0.22) | benign(0.009) | TCGA-53-7624-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | PD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |